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tified through either pharmacy dispensing or provider administration codes. Sev-
eral definitions were applied to identify patients with hemophilia A and B. Health
care utilization and costs for each year were characterized for rFVIIa/FEIBA users.
RESULTS: After excluding 5 states with extensive use of managed care (for which
claimsmay be incomplete), a source population of approximately 63million people
was identified. A total of 130,946 patientsmet the inclusion criteria, of which 10,693
had at least one diagnosis for hemophilia A and 2,032 for hemophilia B. Fewer than
10% were enrolled in managed care in any year. Restricting to males reduced the
sample size to 7292 for hemophilia A (mean age 15.4 years) and 1557 for hemophilia
B (mean age 13.8 years), and these numbers correspond to the expected relative
frequencies of these disorders (4:1). Users of rFVIIa or FEIBAwere approximately 5%
of the cohort and these patients were characterized by extensive use of health care
with on average, a physician visit every 6 weeks and yearly total costs approaching
$1,000,000. CONCLUSIONS: As with any administrative data source, researchers
should be aware of limitations within MAX data, such as the validity of diagnostic
codes and the potential incompleteness of data for certain population subgroups.
Broad demographic coverage, however, large size, and extensive representation of
children make MAX useful, particularly for studying low-prevalence conditions
such as hemophilia.
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OBJECTIVES: The Pain Impact Questionnaire Revised (PIQ-R) is a 6-item patient-
reported measure developed with Item Response Theory and normed against a
general US population sample (GPS). The PIQ-R yields the Pain Impact Score (PIS),
and has been shown to have strong psychometric properties. The traditional stan-
dard PIQ-R uses a 4-week recall; this analysis tested the PIQ-R with a 1-week recall
period. The shorter recall is useful for monitoring interventions with a relatively
rapid impact on pain. METHODS: Identical psychometric tests were run on the
1-week and 4-week PIQ-R using a representative GPS. Internal consistency was
measured with Chronbach’s alpha. Construct validity was tested first by correlat-
ing PIS with a self-reported 0-100 general health rating scale, then by calculating
mean PIS by reported impact of pain condition and other conditions. Discriminant
validity was demonstrated by correlating PIS with the Physical (PCS) and Mental
(MCS) Component Summaries of the SF-12v2 Health Survey. Finally, the unidimen-
sionality of the PIS was explored through factor analysis. RESULTS: Chronbach’s
alpha was .95 for 4-week recall and .96 for 1-week. Correlations between PIS and
general health ratings were strong, at .60 for 4-week recall and .61 for 1-week. The
mean PIS among people with back pain rose monotonically with the reported im-
pact of the condition, for both 1-week and 4-week recall. Conversely, there was no
such rise in PIS by impact of seasonal allergies, which do not generally cause pain.
Among people reporting nomedical conditions,mean PIS in both versionswaswell
below the GPS mean. Both versions of the PIS correlated more strongly with PCS
than with MCS, and exhibited a highly unidimensional structure. CONCLUSIONS:
In all psychometric tests, the 1-week version of the PIQ-R showed nearly identical
results to the 4-week version. Both versions show robust internal consistency,
construct validity, discriminant validity and unidimensionality.
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OBJECTIVES: Little is known about the relative importance to patients and their
willingness to accept tradeoffs among immunoglobulin (IG) treatment administra-
tion attributes. The objective of this study was to quantify patient and parent
preferences for administration attributes of IG treatments. METHODS: United
States adult patients and parents of children with a self-reported physician diag-
nosis of a primary immunodeficiency disorder completed a web-enabled, choice-
format conjoint survey that presented a series of 12 choice questions, each includ-
ing a pair of hypothetical IG-treatment profiles. Each profile was defined by mode,
frequency, location, number of needle sticks, and duration. Before answering the
choice questions, respondents were told to assume all treatments worked equally
well. Choice questionswere based on aD-efficient experimental design. Preference
weights for attribute levelswere estimated using random-parameters logit for each
group. All respondents provided online informed consent. RESULTS: A total of 252
patients and 66 parents completed the choice questions appropriately. Both groups
prefered monthly to weekly, home setting, shorter duration and fewer needle
sticks of IG treatment relative to alternative choices (P  0.05). Mode of adminis-
trationwas the least important attribute to both groups; however, parents strongly
preferred self-administration to an appointment with a health care professional (P
 0.05) whereas patients slightly preferred self-administration butwere indifferent
to the two modes. Overall, 98% of parents and 84% of patients preferred therapy
with options of monthly frequency, home setting, shorter duration, and fewer
needle sticks. CONCLUSIONS: IG treatments that provide the option of a monthly
frequency, home setting, shorter duration, and fewer needle sticks may address
the needs of both patients and parents.
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OBJECTIVES: To estimate the risk of cardiac injury associated with modern radia-
tion in a population of women with different cardiovascular (CV) risk. METHODS:
The data used for this analysis are from the linked SEER-Medicare database. The
study included women aged 66 years and older with stage 0 - III breast cancer
diagnosed between 2000 and 2005. Women were retrospectively categorized into
low, intermediate, or high risk groups based on the presence of certain clinical
diagnosis. The risk for a hospitalization for a cardiac event was estimated using a
multivariable Cox model. RESULTS: The median follow-up time was 40 months.
Among the 91,612 women with AJCC stage 0 - III breast cancer: 39,555 (43.2%) were
treated with radiation therapy and 52,057 (56.8%) were not. Radiation-treated
women were younger, were likely to have pre-existing CV disease, CV risk factors
and more advanced stage at diagnosis (P  0.001). The following baseline charac-
teristics were significant predictors of an increased risk of hospitalization for a
cardiac event: decreasing year of diagnosis (HRs 1.08– 1.19; 95%CI, 1.02– 1.25), age
at diagnosis (HRs 1.59– 2.50; 95%CI, 2.50– 2.61), AJCC stage I – III (HRs 1.13– 1.29;
95% CI, 1.08– 1.38), the number of comorbid conditions (HRs  1.74– 4.35; 95% CI,
1.68– 4.59), and left-sided tumor (HR  1.03; 95% CI, 1.00– 1.06). Chemotherapy did
confer an elevated risk (HR  1.16; 95% CI, 1.12-1.20) for a hospitalized CV event.
The use of radiotherapy in women categorized as high risk for a future CV
event had an increased risk (HR 1.34; 95% CI, 1.29– 1.39) for a hospitalized CV
event compared to thosewith an intermediate risk or low risk.CONCLUSIONS: The
adverse effects of radiation in high risk patients may require the use of techniques
that minimize the heart from radiation exposure.
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OBJECTIVES:There are limited data suggesting that gastrointestinal (GI) conditions
are common in patients with atrial fibrillation (AF). Many agents utilized by pa-
tients with AF, however, are known to increase the risk of GI events. The study
objective was to describe the risk of GI events among patients with AF.METHODS:
Insurance health care claims between January 2005 and December 2009 from the
Thomson Reuters MarketScan® database were analyzed. Subjects aged 18 years
with 180 days of continuous insurance coverage prior to the index AF diagnosis
were selected. GI events were identified from claims with a primary or secondary
diagnosis code for any GI condition. The subset of GI conditions consistent with
dyspepsia was also reported. The risk of GI events was assessed using cumulative
incidence (new GI events/patients without GI condition at baseline) and incidence
rates (IRs; number of patients with an event/patient-years of observation).
RESULTS:A total of 557,123 AF patients were identified, of whom 143,955 (26%) had
a history of a GI condition at baseline. Themean AF patient age was 68.2 years; 45%
were female. Over the 180-day baseline and mean follow-up of 543 days, 308,823
(55.4%) patients had at least one GI event. Dyspepsia was the most common GI
event seen in 29.6% of patients. The cumulative incidences of any GI event and
dyspepsia were 40% and 19%, respectively. The corresponding IRs were 38.8 and
14.7 events per 100 patient–years, respectively. Additionally, during the baseline
period, 359,398 patients (65%) had at least one medication dispensed that had the
potential to cause GI tolerability issues. CONCLUSIONS: In this large claims data-
base, AF was associated with a 40% risk of developing a GI event, predominantly
dyspepsia. Higher propensity for GI events and agents that selectively cause higher
symptomatic GI rates may relate to poor medication adherence in AF patients.
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OBJECTIVES: Post-operative surgical-site infections (SSI) are a leading cause of
prosthetic complications, which include revision surgery. There are insufficient
data to either confirm or refute the hypothesis that post-operative surgical-site
bleeding (SSB) is a mediating pathophysiologic factor linking pharmacologic VTE
prophylaxis to an increased risk of SSI. METHODS: This study addresses this evi-
dence gap by examining the rates and associated risk factors for SSI and yields an
answer on the potential causal relationship between post-discharge thrombopro-
phylaxis, SSB, and subsequent SSI. A cohort of patients with total hip or knee
arthroplasties (from 2005 to 2008) was identified from HealthCore Integrated Re-
searchDatabase (HIRDSM). A random sample of eligible claims recordswas selected
and augmented with the data abstracted from linked hospital medical charts to
conduct a case–control analysis. RESULTS: The study cohort comprised 33,826
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